- Published: 03 June 2014
- Written by Editor
Biocept Expands Breast Cancer Offering
Blood-based OncoCEE-BR(TM) Platform now Includes Estrogen Receptor Testing
SAN DIEGO, June 2, 2014 -- Biocept, Inc. (BIOC), a molecular oncology diagnostics company specializing in biomarker analysis of cell-free circulating tumor DNA and circulating tumor cells (CTCs), today announced the launch of its estrogen receptor (ER) status testing on CTCs that will be performed at the Company's CLIA-certified and CAP-accredited laboratory.
The launch of ER status testing, in conjunction with the Company's HER2 receptor status test, will offer health care providers an additional testing option when a tumor biopsy is unavailable or unsafe. For patients with recurring or newly diagnosed metastatic breast cancer, accurate identification of hormone (ER) and HER2 receptors status plays a major role in treatment outcomes.
"The evaluation of hormone and HER2 receptor status is the standard of care in determining the course of therapy for patients with primary and metastatic breast cancer," said Michael Nall, President and CEO of Biocept. "We believe that our ability to identify hormone and HER2 receptor status will provide diagnostic strategies that could further confirm or even alter the course of a patient's therapy. In addition, our test evaluates the status of these important markers using a simple, non-invasive blood test."
"Our validation study for hormone status provided significant insights into hormone status as it relates to primary and metastatic breast cancers," said Farideh Bischoff Ph.D., Vice President, Translational Research and Clinical Development at Biocept. "We were able to correlate both concordance and discordance of primary biopsy tissue and metastatic biopsy tissue with the CTC status of estrogen receptors."
About Biocept, Inc.
Biocept, Inc., headquartered in San Diego, Calif., is a commercial-stage oncology diagnostics company focused on providing information on patients' tumors to physicians using its proprietary technology platform to help improve individual patient treatment. Biocept has developed proprietary technology platforms for capture and analysis of circulating tumor DNA, both in circulating tumor cells (CTCs) and in plasma (cell free tumor DNA). A standard blood sample is utilized to provide physicians with important prognostic and predictive information to enhance individual treatment of their patients with cancer. Biocept currently offers its OncoCEE-BRTM test for breast cancer and plans to introduce CLIA validated tests for lung, colorectal, prostate and other solid tumors based on its proprietary technology platforms over the coming months.
Forward-Looking Statements Disclaimer Statement
This release contains forward-looking statements that are based upon current expectations or beliefs, as well as a number of assumptions about future events. Although we believe that the expectations reflected in the forward-looking statements and the assumptions upon which they are based are reasonable, we can give no assurance that such expectations and assumptions will prove to have been correct. Forward-looking statements are generally identifiable by the use of words like "may," "will," "should," "could," "expect," "anticipate," "estimate," "believe," "intend," or "project" or the negative of these words or other variations on these words or comparable terminology. To the extent that statements in this release are not strictly historical, including without limitation statements as to our impact on diagnostic strategies, such statements are forward-looking, and are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. The reader is cautioned not to put undue reliance on these forward-looking statements, as these statements are subject to numerous risk factors as set forth in our SEC filings. The effects of such risks and uncertainties could cause actual results to differ materially from the forward-looking statements contained in this release. We do not plan to update any such forward-looking statements and expressly disclaim any duty to update the information contained in this press release except as required by law. Readers are advised to review our filings with the Securities and Exchange Commission, which can be accessed over the Internet at the SEC's website located at www.sec.gov.
Investor Contact: The Ruth Group David Burke (646) 536-7009 This email address is being protected from spambots. You need JavaScript enabled to view it. Media Contact: The Ruth Group Melanie Sollid-Penton (646) 536-7023 This email address is being protected from spambots. You need JavaScript enabled to view it.
